Telix Pharmaceuticals has secured regulatory approval from ANVISA for Illuccix®, the first PSMA-PET prostate cancer
Telix Pharmaceuticals has gained marketing authorization for Illuccix®, its prostate cancer imaging agent, from ANVISA